|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
21st December, 2005
GlaxoSmithKline Donates $1 Million to Rebuilding Efforts in South Asia
GlaxoSmithKline Donates $1 Million to Rebuilding Efforts in South Asia
Philadelphia, PA (December 21, 2005) - GlaxoSmithKline [NYSE:GSK] announced today that it has made a $1 million cash donation to the South Asia Earthquake Relief Fund to help reconstruction efforts following the devastating earthquake in the mountainous regions of South Asiain early October ...
|
19th December, 2005
GSK presents data supporting development of investigational HIV drug brecanavir
GSK presents data supporting development of investigational HIV drug brecanavir
Positive Data for Protease Inhibitor Presented at 45th Annual ICAAC
GlaxoSmithKline (GSK) presented positive results today from a study evaluating the safety, tolerability and antiviral activity of its investigational HIV-1 protease inhibitor (PI), brecanavir* (formerly known as GW640385)1 ...
|
19th December, 2005
First in new class of antibacterials demonstrates promising activity against pathogens commonly found in skin infections
First in new class of antibacterials demonstrates promising activity against pathogens commonly found in skin infections
Studies presented today demonstrated that GlaxoSmithKline’s investigational antibacterial retapamulin showed an excellent microbiology profile and a high degree of in vitro potency in laboratory studies against key pathogens commonly associated with skin and soft tissue infections (SSTI), consistently showing potent activity when compared to other commonly-prescribed topical and oral antimicrobial agents ...
|
17th December, 2005
CERVARIX™, GlaxoSmithKline’s cervical cancer vaccine candidate induced a higher immune response in 10-14 year-old girls versus 15-25 year-old young women
CERVARIX™, GlaxoSmithKline’s cervical cancer vaccine candidate induced a higher immune response in 10-14 year-old girls versus 15-25 year-old young women
Stronger Immune Response Shown Against Cancer-Causing Human Papillomavirus (HPV) Types 16/18 in Adolescent Age Group
Washington DC, 17 December, 2005–Cervarix™, GSK’s candidate cervical cancer vaccine, formulated with the proprietary adjuvant AS04, induced antibody levels against the two most common cancer-causing HPV types (HPV 16/18) at least two-fold higher in 10-14 year old adolescent girls, than in women 15-25 years old, a new study shows ...
|
15th December, 2005
GlaxoSmithKline’s Rotarix™ vaccine against rotavirus receives a positive opinion from the European authorities
GlaxoSmithKline’s Rotarix™ vaccine against rotavirus receives a positive opinion from the European authorities
December 15, 2005, UK, London & Rixensart, Belgium: GlaxoSmithKline Biologicals (GSK Bio) today announced that its vaccine against rotavirus infection, Rotarix™, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the Scientific Committee which evaluates the quality, safety and efficacy of medicinal products in the European Union ...
|
9th December, 2005
FDA Joint Advisory Committee sets date to review GlaxoSmithKline Consumer Healthcare’s proposal for Orlistat 60 (MG) capsules for over-the-counter use
FDA Joint Advisory Committee sets date to review GlaxoSmithKline Consumer Healthcare’s proposal for Orlistat 60 (MG) capsules for over-the-counter use
(Pittsburgh, PA) December 9, 2005 — GlaxoSmithKline (NYSE: GSK) Consumer Healthcare anticipates that on January 23, 2006, the U.S ...
|
9th December, 2005
GlaxoSmithKline initiates trial of Tykerb (lapatinib) in patients with ErbB2-overexpressing breast cancer brain metastasis following Herceptin and cranial radiotherapy
GlaxoSmithKline initiates trial of Tykerb (lapatinib) in patients with ErbB2-overexpressing breast cancer brain metastasis following Herceptin and cranial radiotherapy
SAN ANTONIO, December 9, 2005— GlaxoSmithKline (GSK) has announced the initiation of a global multicenter Phase II trial (known as EGF105084) to evaluate Tykerb (lapatinib) for the treatment of ErbB2-overexpressing (HER2+) breast cancer that has metastasized to the brain ...
|
8th December, 2005
GlaxoSmithKline Acquires Influenza Vaccine Manufacturer ID Biomedical Corporation
GlaxoSmithKline Acquires Influenza Vaccine Manufacturer ID Biomedical Corporation
Issued : Thursday 8 December 2005, London, UK & Philadelphia, US - GlaxoSmithKline plc (NYSE:GSK) today announced the completion of the acquisition of ID Biomedical ...
|
8th December, 2005
Heartfelt wake-up call sounded for heart attack survivors
Heartfelt wake-up call sounded for heart attack survivors
New Survey Uncovers the Life-Changing Effects of a Heart Attack
and Critical Need for Education
Issued – Thursday December 8, 2005, Dallas — A new survey reveals a majority of heart attack survivors characterize their attack as a life-altering “wake-up call,” giving them renewed priorities and a second chance at life ...
|
8th December, 2005
GSK changes Paroxetine Prescribing Information
GSK changes Paroxetine Prescribing Information
Issued - December 8, 2005, PHILADELPHIA, PA – GlaxoSmithKline (NYSE: GSK) has changed the Paxil® (paroxetine hydrochloride) labeling to reflect updated epidemiological studies which show that infants born to women who had first trimester exposure to paroxetine had an increased risk of cardiovascular malformations ...
|
|
|
|
Next 10 » |
|
|
|
|
